HKSTP
ACT Genomics (a leading Asian cancer solution provider) and Sanomics (a lung cancer diagnostics Corp), both companies located in Hong Kong Science Park, had merged under ‘The Hong Kong Science and Technology Parks Corporation (HKSTP) initiative. The merger will create an Asian powerhouse of integrated oncology diagnostic to drive healthcare tech’s global potential in Hong Kong, in the Greater Bay Area, and beyond.
The Next-Gen powerhouse for oncology diagnostic will extend a state-of-the-art and innovative product range like digital PCR, multiple diagnostic technology platforms (including NGS), and ‘gene chips’ for tissue-based as well as liquid-based tests. The portfolio also contains services like clinical applications for covering all different stages of cancer types, companion diagnostics development assistance to pharmaceutical companies, and drug discovery.
